NasVax develops improved vaccines and immunotherapeutic products. The company has four distinct product areas: i. oral anti-CD3 monoclonal antibody immunotherapeutic; ii. VaxiSome® technology, which is an adjuvant-delivery system for enhancing the immunogenicity of vaccines and immunotherapeutics; iii. group-common pneumococcal vaccine, which is a protein-based vaccine that could become the field’s third-generation product; and iv. BBS1-based immunotherapeutics for Alzheimer’s disease.
| Website | http://www.nasvax.com |
| Revenue | $5.5 million |
| Employees | 5 (2 on RocketReach) |
| Founded | 2004 |
| Phone | +1 408-236-7333 |
| Technologies | |
| Industry | Biotechnology, Business Services General, Vaccines & Immunotherapeutic Products, Business Services |
| Keywords | Immunotherapeutics, Vaccine Development, Immunotherapy Research, Therapeutic Vaccines, Vaccine Technology, Vaccine Platform, Antibody Therapeutics, Immuno-Oncology, Drug Discovery, Pharmaceutical Research, Biotechnology, Novel Vaccines, Drug Development, Pharmaceutical Development, Biopharmaceutical |
| Competitors | Moderna Therapeutics, Pfizer, AstraZeneca, Novavax, Sanofi, The Janssen Pharmaceutical Companies of Johnson & Johnson, GSK, Merck & Co., Inc., AbbVie, Bristol Myers Squibb +31 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 73 Companies, SIC Code 737 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Nasvax employee's phone or email?
Nasvax Questions
The Nasvax annual revenue was $5.5 million in 2026.
Erez Chimovits is the CEO of Nasvax.
2 people are employed at Nasvax.
The NAICS codes for Nasvax are [54, 32, 541, 325, 3254].
The SIC codes for Nasvax are [283, 28, 73, 737].
Top Nasvax Employees
-
Erez Chimovits
CEO at Nasvax
San Jose, CA, US4 -
Dorit Kreiner
CFO at Nasvax
Israel
Related Companies
